The Recurrent Glioblastoma Multiforme (GBM) drugs in development market research report provides comprehensive information on the therapeutics under development for Recurrent Glioblastoma Multiforme (GBM), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Recurrent Glioblastoma Multiforme (GBM). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Recurrent Glioblastoma Multiforme (GBM) and features dormant and discontinued products.
GlobalData tracks 164 drugs in development for Recurrent Glioblastoma Multiforme (GBM) by 143 companies/universities/institutes. The top development phase for Recurrent Glioblastoma Multiforme (GBM) is phase ii with 72 drugs in that stage. The Recurrent Glioblastoma Multiforme (GBM) pipeline has 142 drugs in development by companies and 22 by universities/ institutes. Some of the companies in the Recurrent Glioblastoma Multiforme (GBM) pipeline products market are: Bristol-Myers Squibb, AstraZeneca and Incyte.
The key targets in the Recurrent Glioblastoma Multiforme (GBM) pipeline products market include Cells Expressing Epidermal Growth Factor Receptor (Proto Oncogene c ErbB 1 or Receptor Tyrosine Protein Kinase erbB 1 or HER1 or ERBB1 or EGFR or EC 2.7.10.1), Vascular Endothelial Growth Factor Receptor 2 (Fetal Liver Kinase 1 or Kinase Insert Domain Receptor or Protein Tyrosine Kinase Receptor flk 1 or VEGFR2 or CD309 or KDR or EC 2.7.10.1), and Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1).
The key mechanisms of action in the Recurrent Glioblastoma Multiforme (GBM) pipeline product include Cytotoxic To Cells Expressing Epidermal Growth Factor Receptor (Proto Oncogene c ErbB 1 or Receptor Tyrosine Protein Kinase erbB 1 or HER1 or ERBB1 or EGFR or EC 2.7.10.1) with nine drugs in Phase I. The Recurrent Glioblastoma Multiforme (GBM) pipeline products include 23 routes of administration with the top ROA being Intravenous and 16 key molecule types in the Recurrent Glioblastoma Multiforme (GBM) pipeline products market including Small Molecule, and Gene-Modified Cell Therapy.
Recurrent Glioblastoma Multiforme (GBM) overview
Recurrent glioblastoma multiforme (GBM) refers to the return of aggressive brain tumors known as glioblastomas after initial treatment. GBM is the most malignant type of glioma, characterized by rapid growth and infiltrative behavior. Despite aggressive therapies like surgery, radiation, and chemotherapy, GBM often recurs due to its invasive nature and resistance to treatment. Management of recurrent GBM poses significant challenges. Treatment options may include additional surgery, re-irradiation, or alternative chemotherapy regimens. Clinical trials exploring novel therapies, immunotherapy, and targeted approaches aim to improve outcomes for patients facing recurrent GBM. However, the prognosis remains generally poor, emphasizing the critical need for ongoing research and innovative treatments in the field of neuro-oncology.
For a complete picture of Recurrent Glioblastoma Multiforme (GBM)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
